SG11201608077PA - Treatment of nafld and nash - Google Patents

Treatment of nafld and nash

Info

Publication number: SG11201608077PA
Authority: SG; Singapore
Prior art keywords: nafld; nash; treatment
Prior art date: 2014-04-11

Application number

SG11201608077PA

Inventor

Brian Roberts

Xueyan Wang

Yun-Jung Choi

David Karpf

Robert Martin

Charles A Mcwherter

Original Assignee

Cymabay Therapeutics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-04-11

Filing date

2015-04-10

Publication date

2016-10-28

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53373532&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201608077P(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2015-04-10 Application filed by Cymabay Therapeutics Inc filed Critical Cymabay Therapeutics Inc

2016-10-28 Publication of SG11201608077PA publication Critical patent/SG11201608077PA/en

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics

Landscapes

Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Physiology (AREA)
Nutrition Science (AREA)
Obesity (AREA)
Rheumatology (AREA)
Gastroenterology & Hepatology (AREA)
Pain & Pain Management (AREA)
Diabetes (AREA)
Hematology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Separation Using Semi-Permeable Membranes (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

SG11201608077PA 2014-04-11 2015-04-10 Treatment of nafld and nash SG11201608077PA (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201461978335P	2014-04-11	2014-04-11
PCT/US2015/025416 WO2015157697A1 (en)	2014-04-11	2015-04-10	Treatment of nafld and nash

Publications (1)

Publication Number	Publication Date
SG11201608077PA true SG11201608077PA (en)	2016-10-28

Family

ID=53373532

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG11201608077PA SG11201608077PA (en)	2014-04-11	2015-04-10	Treatment of nafld and nash

Country Status (26)

Country	Link
US (7)	US9381181B2 (en)
EP (1)	EP3129018B1 (en)
JP (1)	JP6865038B2 (en)
KR (1)	KR102374499B1 (en)
CN (1)	CN106163508A (en)
AU (1)	AU2015243239B2 (en)
BR (1)	BR112016023269A8 (en)
CA (1)	CA2944139C (en)
CL (1)	CL2016002517A1 (en)
CY (1)	CY1122602T1 (en)
DK (1)	DK3129018T3 (en)
EA (1)	EA036704B1 (en)
ES (1)	ES2764467T3 (en)
HR (1)	HRP20192299T1 (en)
IL (1)	IL248193B (en)
LT (1)	LT3129018T (en)
MX (1)	MX369921B (en)
NZ (1)	NZ724740A (en)
PH (1)	PH12016501978A1 (en)
PL (1)	PL3129018T3 (en)
PT (1)	PT3129018T (en)
RS (1)	RS59637B1 (en)
SG (1)	SG11201608077PA (en)
SI (1)	SI3129018T1 (en)
UA (1)	UA121208C2 (en)
WO (1)	WO2015157697A1 (en)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20110236476A1 (en)	2008-09-02	2011-09-29	Amarin Corporation Plc.	Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same
ES2712052T3 (en)	2008-10-17	2019-05-09	Cymabay Therapeutics Inc	Methods to reduce small and dense LDL particles
BRPI1014405A2 (en)	2009-04-29	2016-04-05	Amarin Corp Plc	pharmaceutical compositions comprising epa and a cardiovascular agent and methods of their use
CA2759284C (en)	2009-04-29	2016-06-21	Amarin Pharma, Inc.	Stable pharmaceutical composition and methods of using same
ES2661217T3 (en)	2009-06-15	2018-03-28	Amarin Pharmaceuticals Ireland Limited	Compositions and methods to reduce triglycerides without increasing LDL-C levels in a subject in simultaneous statin therapy
RU2012116079A (en)	2009-09-23	2013-10-27	АМАРИН КОРПОРЕЙШН ПиЭлСи	PHARMACEUTICAL COMPOSITION, INCLUDING OMEGA-3 FATTY ACID AND HYDROXY DERIVATED STATIN AND WAYS OF ITS APPLICATION
WO2011140441A2 (en)	2010-05-06	2011-11-10	Children's Hospital Medical Center	Methods and systems for converting precursor cells into intestinal tissues through directed differentiation
US11712429B2 (en)	2010-11-29	2023-08-01	Amarin Pharmaceuticals Ireland Limited	Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
EP2646013A4 (en)	2010-11-29	2014-03-26	Amarin Pharma Inc	Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US20130131170A1 (en)	2011-11-07	2013-05-23	Amarin Pharmaceuticals Ireland Limited	Methods of treating hypertriglyceridemia
US11291643B2 (en)	2011-11-07	2022-04-05	Amarin Pharmaceuticals Ireland Limited	Methods of treating hypertriglyceridemia
JP6307442B2 (en)	2012-01-06	2018-04-04	アマリンファーマシューティカルスアイルランドリミテッド	Compositions and methods for reducing the level of high sensitivity (HS-CRP) in a subject
PL3363433T3 (en)	2012-06-29	2021-06-14	Amarin Pharmaceuticals Ireland Limited	Methods of reducing the risk of a cardiovascular event in a subject on statin therapy using eicosapentaenoic acid ethyl ester
US20150265566A1 (en)	2012-11-06	2015-09-24	Amarin Pharmaceuticals Ireland Limited	Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy
US9814733B2 (en) *	2012-12-31	2017-11-14	A,arin Pharmaceuticals Ireland Limited	Compositions comprising EPA and obeticholic acid and methods of use thereof
US20140187633A1 (en)	2012-12-31	2014-07-03	Amarin Pharmaceuticals Ireland Limited	Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9452151B2 (en)	2013-02-06	2016-09-27	Amarin Pharmaceuticals Ireland Limited	Methods of reducing apolipoprotein C-III
US9624492B2 (en)	2013-02-13	2017-04-18	Amarin Pharmaceuticals Ireland Limited	Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en)	2013-02-19	2017-05-30	The Regents Of The University Of Colorado	Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en)	2013-03-14	2016-03-15	Amarin Pharmaceuticals Ireland Limited	Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en)	2013-03-15	2014-09-18	Amarin Pharmaceuticals Ireland Limited	Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en)	2013-06-06	2021-04-06	Amarin Pharmaceuticals Ireland Limited	Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en)	2013-09-04	2015-03-05	Amarin Pharmaceuticals Ireland Limited	Methods of treating or preventing prostate cancer
US9585859B2 (en)	2013-10-10	2017-03-07	Amarin Pharmaceuticals Ireland Limited	Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
CN106102734B (en)	2014-03-20	2019-05-14	西玛贝医药公司	The treatment of intrahepatic cholestasis disease
US10272058B2 (en)	2014-03-20	2019-04-30	Cymabay Therapeutics, Inc.	Treatment of intrahepatic cholestatic diseases
SG11201608077PA (en)	2014-04-11	2016-10-28	Cymabay Therapeutics Inc	Treatment of nafld and nash
CN106661548B (en)	2014-05-28	2020-12-11	儿童医院医疗中心	Methods and systems for converting precursor cells to stomach tissue via directed differentiation
US10561631B2 (en)	2014-06-11	2020-02-18	Amarin Pharmaceuticals Ireland Limited	Methods of reducing RLP-C
US10172818B2 (en)	2014-06-16	2019-01-08	Amarin Pharmaceuticals Ireland Limited	Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
EP3207123A1 (en)	2014-10-17	2017-08-23	Children's Hospital Center D/b/a Cincinnati Children's Hospital Medical Center	In vivo model of human small intestine using pluripotent stem cells and methods of making and using same
CN107530352A (en) *	2015-03-26	2018-01-02	T3D治疗有限责任公司	Use the method for indane acetic acid derivatives treatment hepatopathy
WO2016173923A1 (en)	2015-04-28	2016-11-03	Pronova Biopharma Norge As	Use of structurally enhanced fatty acids containing sulphur for preventing and/or treating non-alcoholic steatohepatitis
WO2017049157A1 (en) *	2015-09-18	2017-03-23	Duke University	Methods and compositions for the treatment of steatosis-associated disorders
WO2017139708A1 (en)	2016-02-10	2017-08-17	Synlogic, Inc.	Bacteria engineered to treat nonalcoholic steatohepatitis (nash)
US10406130B2 (en)	2016-03-15	2019-09-10	Amarin Pharmaceuticals Ireland Limited	Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
US11066650B2 (en)	2016-05-05	2021-07-20	Children's Hospital Medical Center	Methods for the in vitro manufacture of gastric fundus tissue and compositions related to same
GB201614455D0 (en)	2016-08-24	2016-10-05	Univ Oxford Innovation Ltd	Biomarkers
WO2018085622A1 (en) *	2016-11-04	2018-05-11	Children's Hospital Medical Center	Liver organoid disease models and methods of making and using same
US10493363B2 (en) *	2016-11-09	2019-12-03	Activision Publishing, Inc.	Reality-based video game elements
CA3045145A1 (en)	2016-12-05	2018-06-14	Children's Hospital Medical Center	Colonic organoids and methods of making and using same
US11000491B2 (en)	2017-05-05	2021-05-11	Hepanova, Inc.	Amino-aryl-benzamide compounds and methods of use thereof
TW201900160A (en)	2017-05-19	2019-01-01	愛爾蘭商艾瑪琳製藥愛爾蘭有限公司	Compositions and Methods for Lowering Triglycerides in a Subject Having Reduced Kidney Function
US10512622B2 (en)	2017-07-14	2019-12-24	Cymabay Therapeutics, Inc.	Treatment of intrahepatic cholestatic diseases
JP2020533339A (en)	2017-09-13	2020-11-19	ノバルティスアーゲー	Combinations containing FXR agonists
EP3701953A4 (en)	2017-10-27	2021-06-16	Samyang Corporation	Composition for preventing or alleviating nonalcoholic fatty liver disease
IL275002B2 (en)	2017-12-06	2024-04-01	Basf As	Fatty acid derivatives for treating non-alcoholic steatohepatitis
US11058661B2 (en)	2018-03-02	2021-07-13	Amarin Pharmaceuticals Ireland Limited	Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
TN2021000013A1 (en)	2018-09-24	2022-10-03	Amarin Pharmaceuticals Ie Ltd	Methods of reducing the risk of cardiovascular events in a subject
EP3880187A1 (en) *	2018-11-16	2021-09-22	CymaBay Therapeutics, Inc.	Treatment of obesity and its complications
CA3118961A1 (en) *	2018-11-16	2020-05-22	Cymabay Therapeutics, Inc.	Combination treatment of nafld and nash
WO2021097027A1 (en) *	2019-11-14	2021-05-20	Cymabay Therapeutics, Inc.	Seladelpar for use in the treatment of alcoholic liver disease
US20210145775A1 (en) *	2019-11-14	2021-05-20	Cymabay Therapeutics, Inc.	Treatment of intestinal barrier dysfunction and associated diseases
CN115811972A (en) *	2020-05-13	2023-03-17	拓臻制药公司	Combination therapy for liver disorders
KR20240012390A (en)	2021-04-21	2024-01-29	애머린 파마슈티칼스 아일랜드 리미티드	How to Reduce Your Risk of Heart Failure
AU2022274304A1 (en) *	2021-05-11	2023-10-26	Genfit	Ppar-agonists for use in the treatment of liver failure

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7101993B1 (en)	1990-01-11	2006-09-05	Isis Pharmaceuticals, Inc.	Oligonucleotides containing 2′-O-modified purines
US7015315B1 (en)	1991-12-24	2006-03-21	Isis Pharmaceuticals, Inc.	Gapped oligonucleotides
US5739135A (en)	1993-09-03	1998-04-14	Bristol-Myers Squibb Company	Inhibitors of microsomal triglyceride transfer protein and method
US6222025B1 (en)	1995-03-06	2001-04-24	Isis Pharmaceuticals, Inc.	Process for the synthesis of 2′-O-substituted pyrimidines and oligomeric compounds therefrom
US6166197A (en)	1995-03-06	2000-12-26	Isis Pharmaceuticals, Inc.	Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions
SK109198A3 (en)	1996-02-14	1999-06-11	Isis Pharmaceuticals Inc	Sugar-modified gapped oligonucleotides
US5883109A (en)	1996-07-24	1999-03-16	Bristol-Myers Squibb Company	Method for lowering serum lipid levels employing an MTP inhibitor in combination with another cholesterol lowering drug
US6066653A (en)	1997-01-17	2000-05-23	Bristol-Myers Squibb Co.	Method of treating acid lipase deficiency diseases with an MTP inhibitor and cholesterol lowering drugs
US7407943B2 (en)	2001-08-01	2008-08-05	Isis Pharmaceuticals, Inc.	Antisense modulation of apolipoprotein B expression
US7511131B2 (en)	2002-11-13	2009-03-31	Genzyme Corporation	Antisense modulation of apolipoprotein B expression
NZ545943A (en)	2003-09-19	2009-09-25	Janssen Pharmaceutica Nv	4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
RS52825B2 (en)	2004-03-05	2018-03-30	Univ Pennsylvania	Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects
JO3006B1 (en)	2005-09-14	2016-09-05	Janssen Pharmaceutica Nv	Novel Lysine Salts of 4-((Phenoxy Alkyl)Thio)-Phenoxy Acetic Acid Derivatives
WO2008091863A1 (en)	2007-01-23	2008-07-31	Kalypsys, Inc.	Sulfonyl-substituted bicyclic compounds as ppar modulators for the treatment of non-alcoholic steatohepatitis
ES2712052T3 (en)	2008-10-17	2019-05-09	Cymabay Therapeutics Inc	Methods to reduce small and dense LDL particles
JOP20200043A1 (en)	2011-05-10	2017-06-16	Amgen Inc	Methods of treating or preventing cholesterol related disorders
CA2930069A1 (en)	2013-11-20	2015-05-28	Cymabay Therapeutics, Inc.	Treatment of homozygous familial hypercholesterolemia
CN106102734B (en)	2014-03-20	2019-05-14	西玛贝医药公司	The treatment of intrahepatic cholestasis disease
SG11201608077PA (en)	2014-04-11	2016-10-28	Cymabay Therapeutics Inc	Treatment of nafld and nash
WO2015200580A1 (en)	2014-06-26	2015-12-30	Cymabay Therapeutics, Inc.	Treatment of severe hypertriglyceridemia

2015
- 2015-04-10 SG SG11201608077PA patent/SG11201608077PA/en unknown
- 2015-04-10 SI SI201531047T patent/SI3129018T1/en unknown
- 2015-04-10 KR KR1020167031356A patent/KR102374499B1/en active IP Right Grant
- 2015-04-10 EP EP15728222.9A patent/EP3129018B1/en active Active
- 2015-04-10 AU AU2015243239A patent/AU2015243239B2/en active Active
- 2015-04-10 CN CN201580018550.9A patent/CN106163508A/en active Pending
- 2015-04-10 NZ NZ72474015A patent/NZ724740A/en unknown
- 2015-04-10 DK DK15728222.9T patent/DK3129018T3/en active
- 2015-04-10 CA CA2944139A patent/CA2944139C/en active Active
- 2015-04-10 MX MX2016013375A patent/MX369921B/en active IP Right Grant
- 2015-04-10 LT LTEP15728222.9T patent/LT3129018T/en unknown
- 2015-04-10 WO PCT/US2015/025416 patent/WO2015157697A1/en active Application Filing
- 2015-04-10 ES ES15728222T patent/ES2764467T3/en active Active
- 2015-04-10 BR BR112016023269A patent/BR112016023269A8/en not_active Application Discontinuation
- 2015-04-10 UA UAA201609927A patent/UA121208C2/en unknown
- 2015-04-10 US US14/684,100 patent/US9381181B2/en active Active
- 2015-04-10 PL PL15728222T patent/PL3129018T3/en unknown
- 2015-04-10 EA EA201692050A patent/EA036704B1/en unknown
- 2015-04-10 JP JP2016561799A patent/JP6865038B2/en active Active
- 2015-04-10 PT PT157282229T patent/PT3129018T/en unknown
- 2015-04-10 RS RS20191583A patent/RS59637B1/en unknown
2016
- 2016-06-02 US US15/171,910 patent/US9616039B2/en active Active
- 2016-10-04 CL CL2016002517A patent/CL2016002517A1/en unknown
- 2016-10-05 PH PH12016501978A patent/PH12016501978A1/en unknown
- 2016-10-05 IL IL248193A patent/IL248193B/en active IP Right Grant
2017
- 2017-03-02 US US15/447,895 patent/US9962346B2/en active Active
2018
- 2018-04-03 US US15/943,936 patent/US10188620B2/en active Active
- 2018-12-17 US US16/222,379 patent/US10342770B2/en active Active
2019
- 2019-05-23 US US16/420,465 patent/US10722483B2/en active Active
- 2019-12-20 HR HRP20192299TT patent/HRP20192299T1/en unknown
- 2019-12-20 CY CY20191101347T patent/CY1122602T1/en unknown
2020
- 2020-06-19 US US16/906,296 patent/US11179359B2/en active Active

Also Published As

Publication number	Publication date
MX369921B (en)	2019-11-26
CA2944139A1 (en)	2015-10-15
US20150290154A1 (en)	2015-10-15
EP3129018A1 (en)	2017-02-15
US10188620B2 (en)	2019-01-29
SI3129018T1 (en)	2020-02-28
US20190142776A1 (en)	2019-05-16
ES2764467T3 (en)	2020-06-03
HRP20192299T1 (en)	2020-03-06
AU2015243239A1 (en)	2016-10-20
JP6865038B2 (en)	2021-04-28
BR112016023269A2 (en)	2017-08-15
US9962346B2 (en)	2018-05-08
KR102374499B1 (en)	2022-03-14
JP2017513836A (en)	2017-06-01
EA201692050A1 (en)	2017-01-30
RS59637B1 (en)	2020-01-31
US10342770B2 (en)	2019-07-09
US20180008566A1 (en)	2018-01-11
AU2015243239B2 (en)	2019-11-14
KR20160136451A (en)	2016-11-29
IL248193B (en)	2019-03-31
US9381181B2 (en)	2016-07-05
PL3129018T3 (en)	2020-05-18
WO2015157697A1 (en)	2015-10-15
US11179359B2 (en)	2021-11-23
US20210038546A1 (en)	2021-02-11
US20200009092A1 (en)	2020-01-09
US9616039B2 (en)	2017-04-11
PH12016501978A1 (en)	2016-12-19
US20180228752A1 (en)	2018-08-16
LT3129018T (en)	2020-01-10
PT3129018T (en)	2020-01-15
EA036704B1 (en)	2020-12-10
CA2944139C (en)	2020-11-03
UA121208C2 (en)	2020-04-27
US20160324812A1 (en)	2016-11-10
NZ724740A (en)	2019-11-29
CY1122602T1 (en)	2021-03-12
US10722483B2 (en)	2020-07-28
CL2016002517A1 (en)	2017-05-05
BR112016023269A8 (en)	2021-06-29
CN106163508A (en)	2016-11-23
MX2016013375A (en)	2017-02-15
EP3129018B1 (en)	2019-10-23
DK3129018T3 (en)	2020-01-20

Publication	Publication Date	Title
SG11201608077PA (en)	2016-10-28	Treatment of nafld and nash
IL250415B (en)	2020-09-30	Anti-pdl- antibodies and methods of use thereof
IL252839A0 (en)	2017-08-31	Treatment of pemphigus
ZA201607415B (en)	2019-06-26	Antibody-drug-conjugate and its use for the treatment of cancer
ZA201605639B (en)	2019-01-30	Hppd variants and methods of use
ZA201606243B (en)	2019-12-18	Hppd variants and methods of use
GB201404470D0 (en)	2014-04-30	Therapeutic methods and materials
IL282482A (en)	2021-06-30	Protoxin-ii variants and methods of use
IL282508A (en)	2021-06-30	Protoxin-ii variants and methods of use
GB201416832D0 (en)	2014-11-05	Methods of treatment
EP4043567C0 (en)	2024-05-08	Methods and compositions for the treatment of cancer
GB201408297D0 (en)	2014-06-25	Treatment of cancer
GB201511799D0 (en)	2015-08-19	Composition and methods of treatment
GB201605127D0 (en)	2016-05-11	Composition and methods of treatment
GB201417248D0 (en)	2014-11-12	Compostion and methods of treatment
GB201412010D0 (en)	2014-08-20	Treatment of hypertransaminasemia
GB201411150D0 (en)	2014-08-06	Novel aptamers and therapeutic uses thereof
ZA201802201B (en)	2021-07-28	Novel formulation and treatment methods
GB201417456D0 (en)	2014-11-19	Treatment of cancer
GB201404265D0 (en)	2014-04-23	Respiratory analysis and treatment
GB201419559D0 (en)	2014-12-17	Therapeutic compositions and methods
GB201410695D0 (en)	2014-07-30	Uses of oligouronates in cancer treatment
GB201418640D0 (en)	2014-12-03	Agents and methods for treatment of cancer
GB201409262D0 (en)	2014-07-09	Hair treatment compositions and methods
GB201409362D0 (en)	2014-07-09	Treatment of cancer